Gilles Vassal, MD; Olivier Hartmann, MD; Ellen Benhamou, MD
This content is PDF only. Please click on the PDF icon to access.
To the Editor: High-dose busulfan in combination therapy is well known to be responsible for veno-occlusive disease of the liver in about 20% of adult patients undergoing bone marrow transplantation (1, 2). However, the incidence of this disease is lower (0% to 5%) in children (3). In our institution, from September 1979 to December 1990, 403 courses of high-dose chemotherapy were administered before bone marrow transplantation in children with solid tumors: 125 courses included high-dose busulfan. Two total busulfan doses were used: 16 mg/kg body weight in 64 courses and 600 mg/m2 body surface area in 61 courses. The dose
Vassal G, Hartmann O, Benhamou E. Busulfan and Veno-occlusive Disease of the Liver. Ann Intern Med. 1990;112:881. doi: https://doi.org/10.7326/0003-4819-112-11-881_1
Download citation file:
Published: Ann Intern Med. 1990;112(11):881.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use